Abstracts Archive - Page 843 of 2607 - ACR Meeting Abstracts

Abstract Number: 0099 • ACR Convergence 2020
Interleukin 6 Concentration in Synovial Fluid of Patients with Different Types of Arthritis
Aleksandra Bukina¹ and Anna Mihailova¹, ¹Rigas Stradins university, Riga, Latvia
Background/Purpose: Persistent synovitis without known markers such as rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPA) as well as without genetic markers as HLAB27 is not…
Abstract Number: 0100 • ACR Convergence 2020
Concordance Between the QuantiFERON-TB Gold In-Tube and Tuberculin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Rheumatic Diseases
Cristobal Pavez Perales¹, Ana Quiles Rocher², Elena Grau Garcia³, Marta De la Rubia Navarro¹, Samuel Leal Rodriguez⁴, Roxana Gonzalez Mazario¹, Jorge Juan Fragio Gil¹, Cristina Alcañiz Escandell³, Jose Ivorra Cortes¹, Inmaculada Chalmeta Verdejo¹, Luis Gonzalez Puig⁵, Isabel Martinez Cordellat¹, Rosa Negueroles Albuixech¹, Jose Eloy Oller Rodriguez¹, Francisco Miguel Ortiz Sanjuan⁴, Elvira Vicens Bernabeu⁴, Carmen Najera Herranz¹, Ines Canovas Olmos¹ and Jose Andres Roman Ivorra¹, ¹Rheumatology Department. HUP La Fe, Valencia, Spain, ²Medical School, UCV, Valencia, Valencia, Spain, ³Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ⁴Rheumatology Department, HUP La Fe, Valencia, Spain, ⁵Rheumatology Department. HUP La Fe, Torrente ( Valencia), Spain
Background/Purpose: Patients with rheumatic diseases (RD) are at higher risk of latent tuberculosis infection (LTBI) reactivation. To detect and treat it before starting treatment, especially with biological therapies, decrease the reactivation risk. Diagnosis is carried…
Abstract Number: 0101 • ACR Convergence 2020
Romosozumab After Denosumab Improves Lumbar Spine and Maintains Total Hip Bone Mineral Density in Postmenopausal Women with Low Bone Mass
Michael R McClung¹, Michael A Bolognese², Jacques P Brown³, Jean-Yves Reginster⁴, Bente Langdahl⁵, Norma Ruiz-Santiago⁶, Yifei Shi⁶, Maria Rojeski⁶, Jen Timoshanko⁷, Cesar Libanati⁷, Helina Kassahun⁶ and Mary Oates⁶, ¹Oregon Osteoporosis Center, Portland, OR, ²Bethesda Health Research Center, Bethesda, MD, ³Laval University and CHU de Québec (CHUL) Research Centre, Québec City, Canada, ⁴University of Liège, Liège, Belgium, ⁵Aarhus University Hospital, Aarhus, Denmark, ⁶Amgen Inc., Thousand Oaks, CA, ⁷UCB Pharma, Brussels, Belgium
Background/Purpose: Romosozumab, an anti-sclerostin antibody that increases bone formation while decreasing bone resorption, reduces fracture risk within 12 months. Here we evaluate the effects of…
Abstract Number: 0102 • ACR Convergence 2020
Bone Health in Patients with Psoriatic Arthritis in the National Swiss Cohort: A Cross-sectional Study
Diana Camelia Dan¹, Youssef Ibrahimy², Berengere Aubry-Rozier³ and Daniel Aeberli⁴, ¹Lausanne University Hospital, Lausanne, Switzerland, ²University of Lausanne, Lausanne, Switzerland, ³Hôpital orthopédique, Lausanne, Switzerland, ⁴University Hospital of Bern, Bern, Switzerland
Background/Purpose: There is much controversy surrounding the loss of bone mass in patients with psoriasis arthritis (PsA). We wanted to evaluate the prevalence of osteoporosis…
Abstract Number: 0103 • ACR Convergence 2020
The Association of Methotrexate, Sulfasalazine and Hydroxychloroquine Use with Incident Fractures in Postmenopausal Women with Rheumatoid Arthritis: Findings from the Women’s Health Initiative
Rachel Elam¹, Sandeepkumar Gupta², Omar Tolaymat², Sowmya Vasan³, Carolyn Crandall⁴, Jean Wactawski-Wende⁵, Karen Johnson⁶ and Laura Carbone², ¹Augusta University, Evans, GA, ²Augusta University, Augusta, GA, ³WHI, Seattle, WA, ⁴UCLA, Los Angeles, CA, ⁵University of Buffalo, Buffalo, NY, ⁶University of Tennessee Health Sciences Center, Memphis, TN
Background/Purpose: This study was conducted to evaluate the extent to which disease modifying antirheumatic medications (DMARDs) used as part of triple therapy for treatment of…
Abstract Number: 0104 • ACR Convergence 2020
Bone Effects of One-year Tofacitinib Treatment in Rheumatoid Arthritis
Attila Hamar¹, Anita Pusztai², Edit Végh¹, Ágnes Horváth¹, Katalin Gulyás¹, Szilvia Szamosi¹, Zsófia Pethő¹, Nóra Bodnár¹, Boglárka Soós¹, Monika Czókolyová¹, Sándor Szántó¹, Gabriella Szűcs¹, Harjit Bhattoa¹, Gábor Nagy¹, Gábor Tajti¹, Andrea Domján¹, Katalin Hodosi¹ and Zoltán Szekanecz¹, ¹University of Debrecen, Debrecen, Hungary, ²University of Debrecen Faculty of Medicine, Department of Rheumatology, Debrecen, Hungary
Background/Purpose: Oral JAK inhibitor, tofacitinib appeared as a new therapeutic option, beside biological therapies, which has already proven its safety and effectivity in RA, but…
Abstract Number: 0105 • ACR Convergence 2020
Use of Peripheral Quantitative Computed Tomography in the Assessment of Bone Mineral Density in Anti-TNF-treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients
Balázs Juhász¹, Katalin Gulyás¹, Ágnes Horváth¹, Edit Végh¹, Anita Pusztai², Ágnes Szentpétery³, Zsófia Pethő¹, Nóra Bodnár¹, Attila Hamar¹, Levente Bodoki¹, Harjit Bhattoa¹, Éva Szekanecz¹, Katalin Hodosi¹, Andrea Domján¹, Szilvia Szamosi¹, Csaba Horváth⁴, Sándor Szántó¹, Gabriella Szűcs¹, Hennie Raterman⁵, Oliver FitzGerald⁶ and Zoltán Szekanecz¹, ¹University of Debrecen, Debrecen, Hungary, ²University of Debrecen Faculty of Medicine, Department of Rheumatology, Debrecen, Hungary, ³Uppsala University Hospital, Uppsala, Sweden, ⁴Semmelweis University, Budapest, Hungary, ⁵Northwest Clinics, Alkmaar, Netherlands, ⁶Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland
Background/Purpose: Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) have both been associated with generalized and localized bone loss. Inflammatory cytokines like tumor necrosis factor (TNF)…
Abstract Number: 0106 • ACR Convergence 2020
A Machine Learning-derived Radiomics Nomogram for Diagnosis of Osteoporosis and Osteopenia
Qianrong Xie¹, Yue Chen², Yimei Hu³, Fanwei Zeng⁴, Pingxi Wang⁴, Lin Xu⁵, Jianhong Wu⁶, Jie Li¹, Jing Zhu⁷, Ming Xiang⁸ and Fanxin Zeng⁹, ¹Department of Clinical Research Center, Dazhou Central Hospital, Dazhou, China (People's Republic), ²Department of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China (People's Republic), ³Department of Orthopedics, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China (People's Republic), ⁴Department of bone disease, Dazhou Central Hospital, Dazhou, China (People's Republic), ⁵Department of medical imaging, Dazhou Central Hospital, Dazhou, China (People's Republic), ⁶Department of Rheumatology, Dazhou Central Hospital, Dazhou, China (People's Republic), ⁷Department of Rheumatology and Immunology, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Chengdu, China (People's Republic), ⁸Department of Orthopedics, Sichuan Provincial Orthopedic Hospital, Chengdu, China (People's Republic), ⁹Department of Clinical Research Center, Dazhou Central Hospital, Dazhou, Sichuan, China (People's Republic)
Background/Purpose: To discriminate osteoporosis and osteopenia using a quantitative computed tomography (QCT) radiomics signatures and clinical variables.Methods: This retrospective study enrolled 635 patients with QCT images and clinical characteristics from November…
Abstract Number: 0107 • ACR Convergence 2020
Effects of Abaloparatide on Modeling and Remodeling Based Bone Formation
David W Dempster¹, Hua Zhou¹, Sudhaker D Rao², Chris Recknor³, Paul D Miller⁴, Benjamin Z Leder⁵, Miriam Annett⁶, Michael S Ominsky⁶ and Bruce H Mitlak⁶, ¹Regional Bone Center, Helen Hayes Hospital, West Haverstraw, NY, West Haverstraw, NY, ²Bone & Mineral Research Laboratory, Henry Ford Health System, Detroit, MI, Detroit, MI, ³United Osteoporosis Centers, Gainesville, GA, Gainesville, GA, ⁴Colorado Center for Bone Research, Lakewood, CO, Lakewood, CO, ⁵Mass General Hospital, Harvard Medical School, Boston, MA, Boston, MA, ⁶Radius Health, Inc., Waltham, MA, Waltham, MA
Background/Purpose: To evaluate abaloparatide-induced changes in the bone formation indices of mineralizing surface (MS), bone formation rate (BFR) and mineral apposition rate (MAR); and to…
Abstract Number: 0108 • ACR Convergence 2020
The Relationship Between Body Fat Percentage and Bone Mineral Density in Rheumatoid Arthritis Patients
Anastasia- Vasiliki Madenidou¹ and Marwan Bukhari², ¹Rheumatology Department, University Hospitals of Morecambe Bay NHS Trust, Barrow-in-Furness, United Kingdom, ²Rheumatology Department, University Hospitals of Morecambe Bay NHS Trust, Lancaster, United Kingdom
Background/Purpose: Currently, Dual-Energy X-ray Absorptiometry (DEXA) scans are used to determine fracture risk by calculating Bone Mineral Density (BMD). It is well established that body…
Abstract Number: 0109 • ACR Convergence 2020
Glucocorticoid-Induced Osteoporosis: Are We Practicing Prevention?
Eileen Rife¹, Emejuaiwe Nkechinyere² and Jose Leon de la Rocha³, ¹Louisiana State University, Metairie, LA, ²Department of Veterans Affairs, New Orleans, LA, ³Louisiana State University, Auburn, AL
Background/Purpose: Descriptive study designed to assess compliance to evidence-based practice guidelines for the prevention of Glucocorticoid-Induced Osteoporosis (GIOP).Methods: We queried the electronic database of the…
Abstract Number: 0110 • ACR Convergence 2020
Does Urate Directly Influence Bone Turnover? Randomized Controlled Trial of Inosine Supplementation
Nicola Dalbeth¹, Anne Horne², Borislav Mihov¹, Tony Merriman³, Gregory Gamble¹, Lisa Stamp⁴ and Ian Reid¹, ¹University of Auckland, Auckland, New Zealand, ²The University of Auckland, Auckland, New Zealand, ³University of Otago, Dunedin, New Zealand, ⁴University of Otago Christchurch, Christchurch, New Zealand
Background/Purpose: Observational studies have reported that serum urate positively correlates with bone mineral density (BMD) and that hyperuricaemia is protective for the development of osteoporosis…
Abstract Number: 0111 • ACR Convergence 2020
Assessment and Treatment of Glucocorticoid-Induced Osteoporosis in a Rheumatology Clinic
Amanda Stefl¹, Shikha Singla², Jessica Michaud¹, Kama Thomas², Lisa Rein² and Mary Ellen Csuka², ¹Froedtert Hospital, Milwaukee, WI, ²Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Glucocorticoids (GC) are used as a long-term treatment option for an estimated 1% of the US population. The American College of Rheumatology has maintained…
Abstract Number: 0112 • ACR Convergence 2020
Description of Risk Factors at Baseline and Need of Bone Agent According to Hadji Recommendations in Patients Taking Aromatase Inhibitors as Breast Cancer Therapy
David Montero-Seisdedos¹, Oihane Ibarguengoitia-Barrena², Lucía Vega-Álvarez², Carmen Lucía García Gomez², Itziar Calvo-Zorrilla³, Juan M. Blanco-Madrigal², Maria Esther Ruiz-Lucea², María Luz García-Vivar², Eva Galindez-Agirregoikoa², Ana R. Inchaurbe-Pellejero², Olaia Fernandez-Berrizbeitia², Clara E. Perez-Velasquez², Eduardo Cuende-Quintana⁴, Amaia Bilbao-González³ and Iñaki Torre-Salaberri³, ¹Basurto University Hospital, Bilbao, Pais Vasco, Spain, ²Basurto University Hospital, Bilbao, Spain, ³University Hospital of Basurto, Bilbao, Pais Vasco, Spain, ⁴Basurto University Hospital, Madrid, Spain
Background/Purpose: A well-known adverse effect of aromatase inhibitors (AI) in the bone is the loss of mineral density with the consequent increased risk of fracture…
Abstract Number: 0113 • ACR Convergence 2020
Improving Glucocorticoid-Induced Osteoporosis Screening and Management in Patients with Rheumatic Diseases Using the 2017 ACR Guidelines
Marielys Figueroa Sierra¹, Atefeh Vafa¹, Shu Cao², Yuanyuan Lu³, Helen Bateman⁴, John Carter¹, Yih Chang Lin², Raquel Cuchacovich¹, Marcos Maldonado⁴, Joanne Valeriano-Marcet¹ and Gabriela Montes-Rivera⁴, ¹University of South Florida, Tampa, FL, ²University of South Florida, Morsani College of Medicine, Tampa, FL, ³Biostatistician at Graduate Medical Education Department, Tampa, FL, ⁴James A. Haley VA, Tampa, FL
Background/Purpose: Glucocorticoid-induced osteoporosis (GIOP) is a potentially preventable complication in those who are maintained on glucocorticoid (GC) therapy. It is imperative to identify these patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].